Who are bimatoprost solution 0.03 %'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bimatoprost Ophthalmic Solution, Bimatoprost 0.01%, Dorzolamide-timolol and latanoprost, Travoprost 004% sterile ophthalmic solution, Bimatoprost Vehicle, bimatoprost 0.03% ophthalmic solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bimatoprost-solution-0-03.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

bimatoprost solution 0.03 % — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

bimatoprost solution 0.03 % (bimatoprost solution 0.03 %) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin F analog. Area: Ophthalmology.

phase 3 Prostaglandin F analog Prostaglandin F receptor (FP receptor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

bimatoprost solution 0.03 % (bimatoprost solution 0.03 %) — Allergan. Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
bimatoprost solution 0.03 % TARGET	bimatoprost solution 0.03 %	Allergan	phase 3	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Bimatoprost Ophthalmic Solution	Bimatoprost Ophthalmic Solution	Allergan	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Bimatoprost 0.01%	Bimatoprost 0.01%	Allergan	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Dorzolamide-timolol and latanoprost	Dorzolamide-timolol and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)
Travoprost 004% sterile ophthalmic solution	Travoprost 004% sterile ophthalmic solution	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor
Bimatoprost Vehicle	Bimatoprost Vehicle	Allergan	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
bimatoprost 0.03% ophthalmic solution	bimatoprost 0.03% ophthalmic solution	Allergan	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin F analog class)

Allergan · 8 drugs in this class
CHU de Quebec-Universite Laval · 2 drugs in this class
Association for Innovation and Biomedical Research on Light and Image · 2 drugs in this class
Kasr El Aini Hospital · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
SpyGlass Pharma, Inc. · 1 drug in this class
Tun Hussein Onn National Eye Hospital · 1 drug in this class
Universitaire Ziekenhuizen KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bimatoprost solution 0.03 % — Competitive Intelligence Brief. https://druglandscape.com/ci/bimatoprost-solution-0-03. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing